Understanding your treatment and the side effects you may experience

Size: px
Start display at page:

Download "Understanding your treatment and the side effects you may experience"

Transcription

1 Understanding your treatment and the side effects you may experience What does treat? is a prescription medicine used in combination with YERVOY to treat a type of skin cancer called melanoma that has spread or cannot be removed by surgery (advanced melanoma). in combination with YERVOY was approved based on the amount of time patients lived without their tumors worsening. There is ongoing evaluation of clinical benefit of in combination with YERVOY for this use. It is not known if is safe and effective in children less than 18 years of age. (10 mg/ml) and YERVOY (5 mg/ml) are injections for intravenous (IV) use. + YERVOY will not work for every patient. Individual results may vary. Information provided in this brochure is not a substitute for talking with your healthcare professional. Your healthcare professional is the best source of information about your disease. Please see Important Safety Information on pages 23-24, and accompanying U.S. Full Prescribing Information, including Boxed WARNING for YERVOY regarding immune-mediated side effects, and Medication Guides for and YERVOY at the end of this brochure. All models depicted are used for illustrative purposes. 1

2 Your treatment may cause side effects You may have questions or concerns about potential side effects of the + YERVOY Regimen. This journal provides a detailed look at the kind of side effects that may occur. It also gives you a convenient way to track any changes in your health as you start and continue with treatment. If you experience any difference in the way that you feel, even if you re not sure that it s related to a side effect, call your healthcare provider right away for medical advice. Treating side effects as soon as possible may keep problems from becoming more serious. It s important that you do not try to treat symptoms yourself. Don t hesitate to reach out to your oncology treatment team. Remember that YOU are your best healthcare advocate, and that communication is key when it comes to your treatment. What does treat? is a prescription medicine used in combination with YERVOY to treat a type of skin cancer called melanoma that has spread or cannot be removed by surgery (advanced melanoma). in combination with YERVOY was approved based on the amount of time patients lived without their tumors worsening. There is ongoing evaluation of clinical benefit of in combination with YERVOY for this use. It is not known if is safe and effective in children less than 18 years of age. Select Important Safety Information can cause problems that can sometimes become serious or life-threatening and can lead to death. Serious side effects may include lung problems (pneumonitis); intestinal problems (colitis) that can lead to tears or holes in your intestine; liver problems (hepatitis); hormone gland problems (especially the thyroid, pituitary, adrenal glands, and pancreas); kidney problems, including nephritis and kidney failure; skin problems; inflammation of the brain (encephalitis); problems in other organs; and severe infusion reactions. Additional serious side effects of YERVOY alone include: nerve problems that can lead to paralysis; and eye problems. Getting medical treatment right away may keep these problems from becoming more serious. Please see additional Important Safety Information on pages 23-24, and accompanying U.S. Full Prescribing Information, including Boxed WARNING for YERVOY regarding immune-mediated side effects, and Medication Guides for and YERVOY at the end of this brochure. 2

3 + YERVOY works with your immune system to fight metastatic melanoma in 2 ways Stimulate + Recognize YERVOY helps increase the activity of the immune system and stimulates more of the cells that help fight cancer. allows these cells to recognize melanoma and attack it. Because of the way the + YERVOY Regimen works, it can cause your immune system to attack normal organs and tissues in many areas of your body and can affect the way they work. These problems can sometimes become serious or life-threatening and can lead to death. These problems may happen anytime during treatment or even after your treatment has ended. Immune cells are activated and directed toward the melanoma. Your oncologist may prescribe the + YERVOY Regimen because these 2 medications work with your immune system to help fight cancer, but they do it in different ways. Put simply, YERVOY stimulates the kind of cells that fight disease, and allows these cells to recognize melanoma and attack it. While doing so, and YERVOY can also affect non-tumor cells. You may experience side effects These problems may happen anytime during treatment or even after your treatment has ended. Some of these problems may happen more often when is used in combination with YERVOY. See a list of potential side effects on page 5. If you experience severe side effects, your doctor may treat you with corticosteroid or hormone replacement medicines. Your healthcare provider may also need to delay or completely stop treatment. Getting your treatment and YERVOY are 2 different medicines that are delivered into your vein through an intravenous (IV) line. Treatment begins with the combination phase a dose of each medicine every 3 weeks for your first 4 doses. After the combination phase, treatment continues with alone, every 2 weeks. Your healthcare provider will decide how many treatments you need and will do blood tests to check you for side effects. Please see Important Safety Information on pages 23-24, and accompanying U.S. Full Prescribing Information, including Boxed WARNING for YERVOY regarding immune-mediated side effects, and Medication Guides for and YERVOY at the end of this brochure. 3

4 My Health Right Now / / Date Weight lbs Temperature Number of bowel movements daily Number of times you urinate daily Energy level: high medium low Appetite: good average poor Difficulty sleeping? yes no Any shortness of breath? yes no If yes, explain here Assessing how you feel now may make it easier to track side effects moving forward Everyone s body is different, and you know yours better than anyone else. Assessing how your body is feeling right now may make it easier for you to see if you are experiencing any side effects during treatment. Take a few minutes to think about your overall health, and complete the assessment above. Potential side effects are listed on page 5, and there are a number of Side Effects Check-ins throughout the journal. Together with your health baseline, this information provides an important way to monitor your health as your treatment progresses. Please see Important Safety Information on pages 23-24, and accompanying U.S. Full Prescribing Information, including Boxed WARNING for YERVOY regarding immune-mediated side effects, and Medication Guides for (nivolumab) and YERVOY (ipilimumab) at the end of this brochure. 4

5 Possible side effects of the (nivolumab) + YERVOY (ipilimumab) Regimen The + YERVOY Regimen can cause your immune system to attack normal organs and tissues in many areas of your body and can affect the way they work. These problems can sometimes become serious or life-threatening and can lead to death. These problems may happen anytime during treatment or even after your treatment has ended. The most common side effects of, when used in combination with YERVOY include: feeling tired; diarrhea; fever; shortness of breath; rash; nausea; and vomiting. The most common side effects of YERVOY include: tiredness; diarrhea; itching; rash; nausea; vomiting; headache; weight loss; fever; decreased appetite; and difficulty falling or staying asleep. Call or see your healthcare provider right away if you have any of these signs or symptoms or if they get worse: Brain n headache n fever n tiredness or weakness n confusion n memory problems n sleepiness n seeing or hearing things that are not really there (hallucinations) n seizures n stiff neck Liver n yellowing of your skin or the whites of your eyes n severe nausea or vomiting n pain on the right side of your stomach area (abdomen) n drowsiness n dark urine (tea colored) n bleeding or bruise more easily than normal n feeling less hungry than usual Intestines n colitis that can lead to tears or holes in your intestine n diarrhea (loose stools) or more bowel movements than usual n blood in your stools or dark, tarry, sticky stools n severe stomach area (abdomen) pain or tenderness Severe Infusion Reactions Tell your doctor or nurse right away if you get these symptoms during an infusion of : n chills or shaking n itching or rash n flushing n difficulty breathing n dizziness n fever n feeling like passing out Other Organs n changes in eyesight n severe or persistent muscle or joint pains n severe muscle weakness Hormone Glands (especially the thyroid, pituitary, adrenal glands, and pancreas) n headaches that will not go away or unusual headaches n extreme tiredness n weight gain or weight loss n dizziness or fainting n changes in mood or behavior, such as decreased sex drive, irritability, or forgetfulness n hair loss n feeling cold n constipation n voice gets deeper n excessive thirst or lots of urine Lungs n new or worsening cough n chest pain n shortness of breath Kidneys including nephritis and kidney failure n decrease in the amount of urine n blood in your urine n swelling in your ankles n loss of appetite Skin n rash n itching n skin blistering n ulcers in mouth or other mucous membranes Please see additional Important Safety Information on pages 23-24, and accompanying U.S. Full Prescribing Information, including Boxed WARNING for YERVOY regarding immune-mediated side effects, and Medication Guides for and YERVOY at the end of this brochure. 5

6 Side Effects Check-in Combination Phase FIRST DOSE / / Date Check where you are experiencing any side effect Weight lbs Temperature Number of bowel movements daily Number of times you urinate daily Brain Liver Hormone Glands Lungs Energy level: high medium low Appetite: good average poor Kidneys Difficulty sleeping? yes no Any shortness of breath? yes no If yes, explain here Intestines Severe Infusion Reactions Skin Other Organs If you are experiencing any of the side effects listed on page 5, use the chart below to keep track of them. All side effects, even those that may seem mild, such as diarrhea or nausea, should be discussed with your healthcare team right away. This may help keep your side effects from becoming more serious. Use this ranking based on how severe you think your side effects are: Mild Moderate Severe Very Severe Date Side effect(s) you are experiencing How severe? Notes Please see Important Safety Information on pages 23-24, and accompanying U.S. Full Prescribing Information, including Boxed WARNING for YERVOY regarding immune-mediated side effects, and Medication Guides for (nivolumab) and YERVOY (ipilimumab) at the end of this brochure. 6

7 Side Effects Check-in Combination Phase SECOND DOSE / / Date Check where you are experiencing any side effect Weight lbs Temperature Number of bowel movements daily Number of times you urinate daily Brain Liver Hormone Glands Lungs Energy level: high medium low Appetite: good average poor Kidneys Difficulty sleeping? yes no Any shortness of breath? yes no If yes, explain here Intestines Severe Infusion Reactions Skin Other Organs If you are experiencing any of the side effects listed on page 5, use the chart below to keep track of them. All side effects, even those that may seem mild, such as diarrhea or nausea, should be discussed with your healthcare team right away. This may help keep your side effects from becoming more serious. Use this ranking based on how severe you think your side effects are: Mild Moderate Severe Very Severe Date Side effect(s) you are experiencing How severe? Notes Please see Important Safety Information on pages 23-24, and accompanying U.S. Full Prescribing Information, including Boxed WARNING for YERVOY regarding immune-mediated side effects, and Medication Guides for (nivolumab) and YERVOY (ipilimumab) at the end of this brochure. 7

8 Side Effects Check-in Combination Phase THIRD DOSE / / Date Check where you are experiencing any side effect Weight lbs Temperature Number of bowel movements daily Number of times you urinate daily Brain Liver Hormone Glands Lungs Energy level: high medium low Appetite: good average poor Kidneys Difficulty sleeping? yes no Any shortness of breath? yes no If yes, explain here Intestines Severe Infusion Reactions Skin Other Organs If you are experiencing any of the side effects listed on page 5, use the chart below to keep track of them. All side effects, even those that may seem mild, such as diarrhea or nausea, should be discussed with your healthcare team right away. This may help keep your side effects from becoming more serious. Use this ranking based on how severe you think your side effects are: Mild Moderate Severe Very Severe Date Side effect(s) you are experiencing How severe? Notes Please see Important Safety Information on pages 23-24, and accompanying U.S. Full Prescribing Information, including Boxed WARNING for YERVOY regarding immune-mediated side effects, and Medication Guides for (nivolumab) and YERVOY (ipilimumab) at the end of this brochure. 8

9 Side Effects Check-in Combination Phase FOURTH DOSE / / Date Check where you are experiencing any side effect Weight lbs Temperature Number of bowel movements daily Number of times you urinate daily Brain Liver Hormone Glands Lungs Energy level: high medium low Appetite: good average poor Kidneys Difficulty sleeping? yes no Any shortness of breath? yes no If yes, explain here Intestines Severe Infusion Reactions Skin Other Organs If you are experiencing any of the side effects listed on page 5, use the chart below to keep track of them. All side effects, even those that may seem mild, such as diarrhea or nausea, should be discussed with your healthcare team right away. This may help keep your side effects from becoming more serious. Use this ranking based on how severe you think your side effects are: Mild Moderate Severe Very Severe Date Side effect(s) you are experiencing How severe? Notes Please see Important Safety Information on pages 23-24, and accompanying U.S. Full Prescribing Information, including Boxed WARNING for YERVOY regarding immune-mediated side effects, and Medication Guides for (nivolumab) and YERVOY (ipilimumab) at the end of this brochure. 9

10 Side Effects Check-in Alone FIRST DOSE / / Date Check where you are experiencing any side effect Weight lbs Temperature Number of bowel movements daily Number of times you urinate daily Brain Liver Hormone Glands Lungs Energy level: high medium low Appetite: good average poor Kidneys Difficulty sleeping? yes no Any shortness of breath? yes no If yes, explain here Intestines Severe Infusion Reactions Skin Other Organs If you are experiencing any of the side effects listed on page 5, use the chart below to keep track of them. All side effects, even those that may seem mild, such as diarrhea or nausea, should be discussed with your healthcare team right away. This may help keep your side effects from becoming more serious. Use this ranking based on how severe you think your side effects are: Mild Moderate Severe Very Severe Date Side effect(s) you are experiencing How severe? Notes Please see Important Safety Information on pages 23-24, and accompanying U.S. Full Prescribing Information, including Boxed WARNING for YERVOY regarding immune-mediated side effects, and Medication Guides for (nivolumab) and YERVOY (ipilimumab) at the end of this brochure. 10

11 Side Effects Check-in Alone SECOND DOSE / / Date Check where you are experiencing any side effect Weight lbs Temperature Number of bowel movements daily Number of times you urinate daily Brain Liver Hormone Glands Lungs Energy level: high medium low Appetite: good average poor Kidneys Difficulty sleeping? yes no Any shortness of breath? yes no If yes, explain here Intestines Severe Infusion Reactions Skin Other Organs If you are experiencing any of the side effects listed on page 5, use the chart below to keep track of them. All side effects, even those that may seem mild, such as diarrhea or nausea, should be discussed with your healthcare team right away. This may help keep your side effects from becoming more serious. Use this ranking based on how severe you think your side effects are: Mild Moderate Severe Very Severe Date Side effect(s) you are experiencing How severe? Notes Please see Important Safety Information on pages 23-24, and accompanying U.S. Full Prescribing Information, including Boxed WARNING for YERVOY regarding immune-mediated side effects, and Medication Guides for (nivolumab) and YERVOY (ipilimumab) at the end of this brochure. 11

12 Side Effects Check-in Alone THIRD DOSE / / Date Check where you are experiencing any side effect Weight lbs Temperature Number of bowel movements daily Number of times you urinate daily Brain Liver Hormone Glands Lungs Energy level: high medium low Appetite: good average poor Kidneys Difficulty sleeping? yes no Any shortness of breath? yes no If yes, explain here Intestines Severe Infusion Reactions Skin Other Organs If you are experiencing any of the side effects listed on page 5, use the chart below to keep track of them. All side effects, even those that may seem mild, such as diarrhea or nausea, should be discussed with your healthcare team right away. This may help keep your side effects from becoming more serious. Use this ranking based on how severe you think your side effects are: Mild Moderate Severe Very Severe Date Side effect(s) you are experiencing How severe? Notes Please see Important Safety Information on pages 23-24, and accompanying U.S. Full Prescribing Information, including Boxed WARNING for YERVOY regarding immune-mediated side effects, and Medication Guides for (nivolumab) and YERVOY (ipilimumab) at the end of this brochure. 12

13 Side Effects Check-in Alone FOURTH DOSE / / Date Check where you are experiencing any side effect Weight lbs Temperature Number of bowel movements daily Number of times you urinate daily Brain Liver Hormone Glands Lungs Energy level: high medium low Appetite: good average poor Kidneys Difficulty sleeping? yes no Any shortness of breath? yes no If yes, explain here Intestines Severe Infusion Reactions Skin Other Organs If you are experiencing any of the side effects listed on page 5, use the chart below to keep track of them. All side effects, even those that may seem mild, such as diarrhea or nausea, should be discussed with your healthcare team right away. This may help keep your side effects from becoming more serious. Use this ranking based on how severe you think your side effects are: Mild Moderate Severe Very Severe Date Side effect(s) you are experiencing How severe? Notes Please see Important Safety Information on pages 23-24, and accompanying U.S. Full Prescribing Information, including Boxed WARNING for YERVOY regarding immune-mediated side effects, and Medication Guides for (nivolumab) and YERVOY (ipilimumab) at the end of this brochure. 13

14 Side Effects Check-in Alone FIFTH DOSE / / Date Check where you are experiencing any side effect Weight lbs Temperature Number of bowel movements daily Number of times you urinate daily Brain Liver Hormone Glands Lungs Energy level: high medium low Appetite: good average poor Kidneys Difficulty sleeping? yes no Any shortness of breath? yes no If yes, explain here Intestines Severe Infusion Reactions Skin Other Organs If you are experiencing any of the side effects listed on page 5, use the chart below to keep track of them. All side effects, even those that may seem mild, such as diarrhea or nausea, should be discussed with your healthcare team right away. This may help keep your side effects from becoming more serious. Use this ranking based on how severe you think your side effects are: Mild Moderate Severe Very Severe Date Side effect(s) you are experiencing How severe? Notes Please see Important Safety Information on pages 23-24, and accompanying U.S. Full Prescribing Information, including Boxed WARNING for YERVOY regarding immune-mediated side effects, and Medication Guides for (nivolumab) and YERVOY (ipilimumab) at the end of this brochure. 14

15 Side Effects Check-in Alone SIXTH DOSE / / Date Check where you are experiencing any side effect Weight lbs Temperature Number of bowel movements daily Number of times you urinate daily Brain Liver Hormone Glands Lungs Energy level: high medium low Appetite: good average poor Kidneys Difficulty sleeping? yes no Any shortness of breath? yes no If yes, explain here Intestines Severe Infusion Reactions Skin Other Organs If you are experiencing any of the side effects listed on page 5, use the chart below to keep track of them. All side effects, even those that may seem mild, such as diarrhea or nausea, should be discussed with your healthcare team right away. This may help keep your side effects from becoming more serious. Use this ranking based on how severe you think your side effects are: Mild Moderate Severe Very Severe Date Side effect(s) you are experiencing How severe? Notes Please see Important Safety Information on pages 23-24, and accompanying U.S. Full Prescribing Information, including Boxed WARNING for YERVOY regarding immune-mediated side effects, and Medication Guides for (nivolumab) and YERVOY (ipilimumab) at the end of this brochure. 15

16 Side Effects Check-in Alone SEVENTH DOSE / / Date Check where you are experiencing any side effect Weight lbs Temperature Number of bowel movements daily Number of times you urinate daily Brain Liver Hormone Glands Lungs Energy level: high medium low Appetite: good average poor Kidneys Difficulty sleeping? yes no Any shortness of breath? yes no If yes, explain here Intestines Severe Infusion Reactions Skin Other Organs If you are experiencing any of the side effects listed on page 5, use the chart below to keep track of them. All side effects, even those that may seem mild, such as diarrhea or nausea, should be discussed with your healthcare team right away. This may help keep your side effects from becoming more serious. Use this ranking based on how severe you think your side effects are: Mild Moderate Severe Very Severe Date Side effect(s) you are experiencing How severe? Notes Please see Important Safety Information on pages 23-24, and accompanying U.S. Full Prescribing Information, including Boxed WARNING for YERVOY regarding immune-mediated side effects, and Medication Guides for (nivolumab) and YERVOY (ipilimumab) at the end of this brochure. 16

17 Side Effects Check-in Alone EIGHTH DOSE / / Date Check where you are experiencing any side effect Weight lbs Temperature Number of bowel movements daily Number of times you urinate daily Brain Liver Hormone Glands Lungs Energy level: high medium low Appetite: good average poor Kidneys Difficulty sleeping? yes no Any shortness of breath? yes no If yes, explain here Intestines Severe Infusion Reactions Skin Other Organs If you are experiencing any of the side effects listed on page 5, use the chart below to keep track of them. All side effects, even those that may seem mild, such as diarrhea or nausea, should be discussed with your healthcare team right away. This may help keep your side effects from becoming more serious. Use this ranking based on how severe you think your side effects are: Mild Moderate Severe Very Severe Date Side effect(s) you are experiencing How severe? Notes Please see Important Safety Information on pages 23-24, and accompanying U.S. Full Prescribing Information, including Boxed WARNING for YERVOY regarding immune-mediated side effects, and Medication Guides for (nivolumab) and YERVOY (ipilimumab) at the end of this brochure. 17

18 Side Effects Check-in Alone NINTH DOSE / / Date Check where you are experiencing any side effect Weight lbs Temperature Number of bowel movements daily Number of times you urinate daily Brain Liver Hormone Glands Lungs Energy level: high medium low Appetite: good average poor Kidneys Difficulty sleeping? yes no Any shortness of breath? yes no If yes, explain here Intestines Severe Infusion Reactions Skin Other Organs If you are experiencing any of the side effects listed on page 5, use the chart below to keep track of them. All side effects, even those that may seem mild, such as diarrhea or nausea, should be discussed with your healthcare team right away. This may help keep your side effects from becoming more serious. Use this ranking based on how severe you think your side effects are: Mild Moderate Severe Very Severe Date Side effect(s) you are experiencing How severe? Notes Please see Important Safety Information on pages 23-24, and accompanying U.S. Full Prescribing Information, including Boxed WARNING for YERVOY regarding immune-mediated side effects, and Medication Guides for (nivolumab) and YERVOY (ipilimumab) at the end of this brochure. 18

19 Side Effects Check-in Alone TENTH DOSE / / Date Check where you are experiencing any side effect Weight lbs Temperature Number of bowel movements daily Number of times you urinate daily Brain Liver Hormone Glands Lungs Energy level: high medium low Appetite: good average poor Kidneys Difficulty sleeping? yes no Any shortness of breath? yes no If yes, explain here Intestines Severe Infusion Reactions Skin Other Organs If you are experiencing any of the side effects listed on page 5, use the chart below to keep track of them. All side effects, even those that may seem mild, such as diarrhea or nausea, should be discussed with your healthcare team right away. This may help keep your side effects from becoming more serious. Use this ranking based on how severe you think your side effects are: Mild Moderate Severe Very Severe Date Side effect(s) you are experiencing How severe? Notes Please see Important Safety Information on pages 23-24, and accompanying U.S. Full Prescribing Information, including Boxed WARNING for YERVOY regarding immune-mediated side effects, and Medication Guides for (nivolumab) and YERVOY (ipilimumab) at the end of this brochure. 19

20 Side Effects Check-in Alone ELEVENTH DOSE / / Date Check where you are experiencing any side effect Weight lbs Temperature Number of bowel movements daily Number of times you urinate daily Brain Liver Hormone Glands Lungs Energy level: high medium low Appetite: good average poor Kidneys Difficulty sleeping? yes no Any shortness of breath? yes no If yes, explain here Intestines Severe Infusion Reactions Skin Other Organs If you are experiencing any of the side effects listed on page 5, use the chart below to keep track of them. All side effects, even those that may seem mild, such as diarrhea or nausea, should be discussed with your healthcare team right away. This may help keep your side effects from becoming more serious. Use this ranking based on how severe you think your side effects are: Mild Moderate Severe Very Severe Date Side effect(s) you are experiencing How severe? Notes Please see Important Safety Information on pages 23-24, and accompanying U.S. Full Prescribing Information, including Boxed WARNING for YERVOY regarding immune-mediated side effects, and Medication Guides for (nivolumab) and YERVOY (ipilimumab) at the end of this brochure. 20

21 Side Effects Check-in Alone Additional Chart as Needed / / Date Check where you are experiencing any side effect Weight lbs Temperature Number of bowel movements daily Number of times you urinate daily Brain Liver Hormone Glands Lungs Energy level: high medium low Appetite: good average poor Kidneys Difficulty sleeping? yes no Any shortness of breath? yes no If yes, explain here Intestines Severe Infusion Reactions Skin Other Organs If you are experiencing any of the side effects listed on page 5, use the chart below to keep track of them. All side effects, even those that may seem mild, such as diarrhea or nausea, should be discussed with your healthcare team right away. This may help keep your side effects from becoming more serious. Use this ranking based on how severe you think your side effects are: Mild Moderate Severe Very Severe Date Side effect(s) you are experiencing How severe? Notes Please see Important Safety Information on pages 23-24, and accompanying U.S. Full Prescribing Information, including Boxed WARNING for YERVOY regarding immune-mediated side effects, and Medication Guides for (nivolumab) and YERVOY (ipilimumab) at the end of this brochure. 21

22 Important Contact Information Oncologist s name Phone number address Nurse s name Phone number address Other healthcare provider s name Phone number address Health insurance provider Phone number Keep the lines of communication open + YERVOY combination therapy may offer you a way to fight advanced melanoma, but there is the very real potential for side effects. The important thing is to keep the lines of communication open with your oncology team. Personalized Care Counselor Support Patients can sign up for the option to speak with a registered nurse who can respond to questions about treatment and help you to be an informed partner with your doctor. Care Counselors cannot offer medical advice. Your healthcare professional is the best source of information about your health. For more information, visit or call ( ). Please see Important Safety Information on pages 23-24, and accompanying U.S. Full Prescribing Information, including Boxed WARNING for YERVOY regarding immune-mediated side effects, and Medication Guides for and YERVOY at the end of this brochure. 22

23 Important Safety Information Important Safety Information about (nivolumab) in combination with YERVOY (ipilimumab) is a medicine that may treat your melanoma by working with your immune system. can cause your immune system to attack normal organs and tissues in many areas of your body and can affect the way they work. These problems can sometimes become serious or life-threatening and can lead to death. These problems may happen anytime during treatment or even after your treatment has ended. Some of these problems may happen more often when is used in combination with YERVOY. YERVOY can cause serious side effects in many parts of your body which can lead to death. These problems may happen anytime during treatment with YERVOY or after you have completed treatment. Serious side effects may include: n Lung problems (pneumonitis). Symptoms of pneumonitis may include: new or worsening cough; chest pain; and shortness of breath. n Intestinal problems (colitis) that can lead to tears or holes in your intestine. Signs and symptoms of colitis may include: diarrhea (loose stools) or more bowel movements than usual; blood in your stools or dark, tarry, sticky stools; and severe stomach area (abdomen) pain or tenderness. n Liver problems (hepatitis). Signs and symptoms of hepatitis may include: yellowing of your skin or the whites of your eyes; severe nausea or vomiting; pain on the right side of your stomach area (abdomen); drowsiness; dark urine (tea colored); bleeding or bruising more easily than normal; and feeling less hungry than usual. n Hormone gland problems (especially the thyroid, pituitary, adrenal glands, and pancreas). Signs and symptoms that your hormone glands are not working properly may include: headaches that will not go away or unusual headaches; extreme tiredness; weight gain or weight loss; dizziness or fainting; changes in mood or behavior, such as decreased sex drive, irritability, or forgetfulness; hair loss; feeling cold; constipation; voice gets deeper; and excessive thirst or lots of urine. n Kidney problems, including nephritis and kidney failure. Signs of kidney problems may include: decrease in the amount of urine; blood in your urine; swelling in your ankles; and loss of appetite. n Skin problems. Signs of these problems may include: rash; itching; skin blistering; and ulcers in the mouth or other mucous membranes. n Inflammation of the brain (encephalitis). Signs and symptoms of encephalitis may include: headache; fever; tiredness or weakness; confusion; memory problems; sleepiness; seeing or hearing things that are not really there (hallucinations); seizures; and stiff neck. n Problems in other organs. Signs of these problems may include: changes in eyesight; severe or persistent muscle or joint pains; and severe muscle weakness. Additional serious side effects observed during a separate study of YERVOY alone include: n Nerve problems that can lead to paralysis. Symptoms of nerve problems may include: unusual weakness of legs, arms, or face; and numbness or tingling in hands or feet. n Eye problems. Symptoms may include: blurry vision, double vision, or other vision problems; and eye pain or redness. Getting medical treatment right away may keep these problems from becoming more serious. Your healthcare provider will check you for these problems during treatment. Your healthcare provider may treat you with corticosteroid or hormone replacement medicines. Your healthcare provider may also need to delay or completely stop treatment, if you have severe side effects. (continued on next page) Please see accompanying U.S. Full Prescribing Information, including Boxed WARNING for YERVOY regarding immune-mediated side effects, and Medication Guides for and YERVOY at the end of this brochure. 23

24 Important Safety Information (continued) can cause serious side effects, including: n Severe infusion reactions. Tell your doctor or nurse right away if you get these symptoms during an infusion of : chills or shaking; itching or rash; flushing; difficulty breathing; dizziness; fever; and feeling like passing out. Pregnancy and Nursing: n Tell your healthcare provider if you are pregnant or plan to become pregnant. and YERVOY can harm your unborn baby. Females who are able to become pregnant should use an effective method of birth control during and for at least 5 months after the last dose of. Talk to your healthcare provider about birth control methods that you can use during this time. Tell your healthcare provider right away if you become pregnant or think you are pregnant during treatment. You or your healthcare provider should contact Bristol-Myers Squibb at as soon as you become aware of the pregnancy. n Pregnancy Safety Surveillance Study: Females who become pregnant during treatment with YERVOY are encouraged to enroll in a Pregnancy Safety Surveillance Study. The purpose of this study is to collect information about the health of you and your baby. You or your healthcare provider can enroll in the Pregnancy Safety Surveillance Study by calling n Before receiving treatment, tell your healthcare provider if you are breastfeeding or plan to breastfeed. It is not known if either treatment passes into your breast milk. Do not breastfeed during treatment and for 3 months after the last dose of YERVOY. Tell your healthcare provider about: n Your health problems or concerns if you: have immune system problems such as autoimmune disease, Crohn s disease, ulcerative colitis, lupus, or sarcoidosis; have had an organ transplant; have lung or breathing problems; have liver problems; or have any other medical conditions. n All the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. The most common side effects of, when used in combination with YERVOY include: feeling tired; diarrhea; fever; shortness of breath; rash; nausea; and vomiting. The most common side effects of YERVOY include: tiredness; diarrhea; itching; rash; nausea; vomiting; headache; weight loss; fever; decreased appetite; and difficulty falling or staying asleep. These are not all the possible side effects. For more information, ask your healthcare provider or pharmacist. Call your doctor for medical advice about side effects. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit or call FDA You may also report side effects to Bristol-Myers Squibb at Please see accompanying U.S. Full Prescribing Information, including Boxed WARNING for YERVOY regarding immune-mediated side effects, and Medication Guides for and YERVOY at the end of this brochure. 24

25 For more information, call or visit Bristol-Myers Squibb is committed to helping patients throughout their + YERVOY Regimen treatment., YERVOY, and the related logos are trademarks of Bristol-Myers Squibb Company Bristol-Myers Squibb Company. All rights reserved. Printed in USA. 7356US /18 Please see Important Safety Information on pages 23-24, and accompanying U.S. Full Prescribing Information, including Boxed WARNING for YERVOY regarding immune-mediated side effects, and Medication Guides for and YERVOY at the end of this brochure. 25

26 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use safely and effectively. See full prescribing information for. (nivolumab) injection, for intravenous use Initial U.S. Approval: RECENT MAJOR CHANGES Indications and Usage (1) 12/2017 Dosage and Administration (2) 1/2018 Warnings and Precautions, Immune-Mediated Hepatitis (5.3) 9/2017 Warnings and Precautions, Other Immune-Mediated Adverse Reactions (5.8) 9/2017 Warnings and Precautions, Infusion Reactions (5.9) 1/ INDICATIONS AND USAGE is a programmed death receptor-1 (PD-1) blocking antibody indicated for the treatment of: patients with BRAF V600 wild-type unresectable or metastatic melanoma, as a single agent. (1.1) patients with BRAF V600 mutation-positive unresectable or metastatic melanoma, as a single agent. a (1.1) patients with unresectable or metastatic melanoma, in combination with ipilimumab. a (1.1) patients with melanoma with lymph node involvement or metastatic disease who have undergone complete resection, in the adjuvant setting. (1.2) patients with metastatic non-small cell lung cancer and progression on or after platinum-based chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving. (1.3) patients with advanced renal cell carcinoma who have received prior antiangiogenic therapy. (1.4) adult patients with classical Hodgkin lymphoma that has relapsed or progressed after b : (1.5) autologous hematopoietic stem cell transplantation (HSCT) and brentuximab vedotin, or 3 or more lines of systemic therapy that includes autologous HSCT. patients with recurrent or metastatic squamous cell carcinoma of the head and neck with disease progression on or after a platinum-based therapy. (1.6) patients with locally advanced or metastatic urothelial carcinoma who b : have disease progression during or following platinum-containing chemotherapy have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. (1.7) adult and pediatric (12 years and older) patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dmmr) metastatic colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan. b (1.8) patients with hepatocellular carcinoma who have been previously treated with sorafenib. b (1.9) a This indication is approved under accelerated approval based on progression-free survival. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials. b This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials DOSAGE AND ADMINISTRATION Administer as an intravenous infusion. Unresectable or metastatic melanoma 240 mg every 2 weeks. (2.1) with ipilimumab: 1 mg/kg, followed by ipilimumab on the same day, every 3 weeks for 4 doses, then 240 mg every 2 weeks. (2.1) Adjuvant treatment of melanoma 240 mg every 2 weeks. (2.2) Metastatic non-small cell lung cancer 240 mg every 2 weeks. (2.3) Advanced renal cell carcinoma 240 mg every 2 weeks. (2.4) FULL PRESCRIBING INFORMATION: CONTENTS* 1 INDICATIONS AND USAGE 1.1 Unresectable or Metastatic Melanoma 1.2 Adjuvant Treatment of Melanoma 1.3 Metastatic Non-Small Cell Lung Cancer 1.4 Renal Cell Carcinoma 1.5 Classical Hodgkin Lymphoma 1.6 Squamous Cell Carcinoma of the Head and Neck 1.7 Urothelial Carcinoma 1.8 Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dmmr) Metastatic Colorectal Cancer 1.9 Hepatocellular Carcinoma Classical Hodgkin lymphoma (nivolumab) 3 mg/kg every 2 weeks. (2.5) Recurrent or metastatic squamous cell carcinoma of the head and neck 3 mg/kg every 2 weeks. (2.6) Locally advanced or metastatic urothelial carcinoma 240 mg every 2 weeks (2.7) Microsatellite instability-high (MSI-H) or mismatch repair deficient (dmmr) metastatic colorectal cancer 240 mg every 2 weeks. (2.8) Hepatocellular carcinoma 240 mg every 2 weeks. (2.9) DOSAGE FORMS AND STRENGTHS Injection: 40 mg/4 ml, 100 mg/10 ml, and 240 mg/24 ml solution in a single-dose vial. (3) CONTRAINDICATIONS None. (4) WARNINGS AND PRECAUTIONS Immune-mediated pneumonitis: Withhold for moderate and permanently discontinue for severe or life-threatening pneumonitis. (5.1) Immune-mediated colitis: Withhold when given as a single agent for moderate or severe and permanently discontinue for life-threatening colitis. Withhold when given with ipilimumab for moderate and permanently discontinue for severe or life-threatening colitis. (5.2) Immune-mediated hepatitis: Monitor for changes in liver function. Withhold for moderate and permanently discontinue for severe or life-threatening transaminase or total bilirubin elevation. (5.3) Immune-mediated endocrinopathies: Withhold for moderate or severe and permanently discontinue for life-threatening hypophysitis. Withhold for moderate and permanently discontinue for severe or life-threatening adrenal insufficiency. Monitor for changes in thyroid function. Initiate thyroid hormone replacement as needed. Monitor for hyperglycemia. Withhold for severe and permanently discontinue for life-threatening hyperglycemia. (5.4) Immune-mediated nephritis and renal dysfunction: Monitor for changes in renal function. Withhold for moderate or severe and permanently discontinue for life-threatening serum creatinine elevation. (5.5) Immune-mediated skin adverse reactions: Withhold for severe and permanently discontinue for life-threatening rash. (5.6) Immune-mediated encephalitis: Monitor for changes in neurologic function. Withhold for new-onset moderate to severe neurological signs or symptoms and permanently discontinue for immune-mediated encephalitis. (5.7) Infusion reactions: Discontinue for severe and life-threatening infusion reactions. Interrupt or slow the rate of infusion in patients with mild or moderate infusion reactions. (5.9) Complications of allogeneic HSCT after : Monitor for hyperacute graftversus-host-disease (GVHD), grade acute GVHD, steroid-requiring febrile syndrome, hepatic veno-occlusive disease, and other immune-mediated adverse reactions. Transplant-related mortality has occurred. (5.10) Embryo-fetal toxicity: Can cause fetal harm. Advise of potential risk to a fetus and use of effective contraception. (5.11, 8.1, 8.3) ADVERSE REACTIONS Most common adverse reactions ( 20%) in patients were: as a single agent: fatigue, rash, musculoskeletal pain, pruritus, diarrhea, nausea, asthenia, cough, dyspnea, constipation, decreased appetite, back pain, arthralgia, upper respiratory tract infection, pyrexia, headache, and abdominal pain. (6.1) with ipilimumab: fatigue, rash, diarrhea, nausea, pyrexia, vomiting, and dyspnea. (6.1) To report SUSPECTED ADVERSE REACTIONS, contact Bristol-Myers Squibb at or FDA at FDA-1088 or USE IN SPECIFIC POPULATIONS Lactation: Discontinue breastfeeding. (8.2) See 17 for PATIENT COUNSELING INFORMATION and Medication Guide. Revised: 1/ DOSAGE AND ADMINISTRATION 2.1 Recommended Dosage for Unresectable or Metastatic Melanoma 2.2 Recommended Dosage for Adjuvant Treatment of Melanoma 2.3 Recommended Dosage for NSCLC 2.4 Recommended Dosage for RCC 2.5 Recommended Dosage for chl 2.6 Recommended Dosage for SCCHN 2.7 Recommended Dosage for Urothelial Carcinoma 2.8 Recommended Dosage for CRC 2.9 Recommended Dosage for HCC 2.10 Dose Modifications 2.11 Preparation and Administration (Continued)

27 FULL PRESCRIBING INFORMATION: CONTENTS* (Continued) 3 DOSAGE FORMS AND STRENGTHS 4 CONTRAINDICATIONS 5 WARNINGS AND PRECAUTIONS 5.1 Immune-Mediated Pneumonitis 5.2 Immune-Mediated Colitis 5.3 Immune-Mediated Hepatitis 5.4 Immune-Mediated Endocrinopathies 5.5 Immune-Mediated Nephritis and Renal Dysfunction 5.6 Immune-Mediated Skin Adverse Reactions 5.7 Immune-Mediated Encephalitis 5.8 Other Immune-Mediated Adverse Reactions 5.9 Infusion Reactions 5.10 Complications of Allogeneic HSCT after 5.11 Embryo-Fetal Toxicity 6 ADVERSE REACTIONS 6.1 Clinical Trials Experience 6.2 Immunogenicity 7 DRUG INTERACTIONS 8 USE IN SPECIFIC POPULATIONS 8.1 Pregnancy 8.2 Lactation 8.3 Females and Males of Reproductive Potential 8.4 Pediatric Use 8.5 Geriatric Use 8.6 Renal Impairment 8.7 Hepatic Impairment 10 OVERDOSAGE 11 DESCRIPTION 12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action 12.2 Pharmacodynamics 12.3 Pharmacokinetics 13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility 13.2 Animal Toxicology and/or Pharmacology 14 CLINICAL STUDIES 14.1 Unresectable or Metastatic Melanoma 14.2 Adjuvant Treatment of Melanoma 14.3 Metastatic Non-Small Cell Lung Cancer (NSCLC) 14.4 Renal Cell Carcinoma 14.5 Classical Hodgkin Lymphoma 14.6 Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN) 14.7 Urothelial Carcinoma 14.8 Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dmmr) Metastatic Colorectal Cancer 14.9 Hepatocellular Carcinoma 16 HOW SUPPLIED/STORAGE AND HANDLING 17 PATIENT COUNSELING INFORMATION *Sections or subsections omitted from the full prescribing information are not listed. FULL PRESCRIBING INFORMATION 1 INDICATIONS AND USAGE 1.1 Unresectable or Metastatic Melanoma (nivolumab) as a single agent is indicated for the treatment of patients with BRAF V600 wild-type unresectable or metastatic melanoma [see Clinical Studies (14.1)]. as a single agent is indicated for the treatment of patients with BRAF V600 mutation-positive unresectable or metastatic melanoma [see Clinical Studies (14.1)]. This indication is approved under accelerated approval based on progression-free survival. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials., in combination with ipilimumab, is indicated for the treatment of patients with unresectable or metastatic melanoma [see Clinical Studies (14.1)]. This indication is approved under accelerated approval based on progression-free survival. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials. 1.2 Adjuvant Treatment of Melanoma is indicated for the adjuvant treatment of patients with melanoma with involvement of lymph nodes or metastatic disease who have undergone complete resection [see Clinical Studies (14.2)]. 1.3 Metastatic Non-Small Cell Lung Cancer is indicated for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with progression on or after platinum-based chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving [see Clinical Studies (14.3)]. 1.4 Renal Cell Carcinoma is indicated for the treatment of patients with advanced renal cell carcinoma (RCC) who have received prior anti-angiogenic therapy [see Clinical Studies (14.4)]. 1.5 Classical Hodgkin Lymphoma is indicated for the treatment of adult patients with classical Hodgkin lymphoma (chl) that has relapsed or progressed after: autologous hematopoietic stem cell transplantation (HSCT) and brentuximab vedotin, or 3 or more lines of systemic therapy that includes autologous HSCT. This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials [see Clinical Studies (14.5)]. 1.6 Squamous Cell Carcinoma of the Head and Neck is indicated for the treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) with disease progression on or after platinum-based therapy [see Clinical Studies (14.6)]. 1.7 Urothelial Carcinoma (nivolumab) is indicated for the treatment of patients with locally advanced or metastatic urothelial carcinoma who: have disease progression during or following platinum-containing chemotherapy have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. This indication is approved under accelerated approval based on tumor response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials [see Clinical Studies (14.7)]. 1.8 Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dmmr) Metastatic Colorectal Cancer is indicated for the treatment of adult and pediatric patients 12 years and older with microsatellite instability-high (MSI-H) or mismatch repair deficient (dmmr) metastatic colorectal cancer (CRC) that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan [see Clinical Studies (14.8)]. This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials. 1.9 Hepatocellular Carcinoma is indicated for the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib. This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials [see Clinical Studies (14.9)]. 2 DOSAGE AND ADMINISTRATION 2.1 Recommended Dosage for Unresectable or Metastatic Melanoma The recommended dose of as a single agent is 240 mg administered as an intravenous infusion over 30 minutes every 2 weeks until disease progression or unacceptable toxicity. The recommended dose of is 1 mg/kg administered as an intravenous infusion over 30 minutes, followed by ipilimumab on the same day, every 3 weeks for 4 doses [see Clinical Studies (14.1)]. The recommended subsequent dose of, as a single agent, is 240 mg administered as an intravenous infusion over 30 minutes every 2 weeks until disease progression or unacceptable toxicity. Review the Full Prescribing Information for ipilimumab prior to initiation. 2.2 Recommended Dosage for Adjuvant Treatment of Melanoma The recommended dose of is 240 mg administered as an intravenous infusion over 60 minutes every 2 weeks until disease recurrence or unacceptable toxicity for up to 1 year. 2.3 Recommended Dosage for NSCLC The recommended dose of is 240 mg administered as an intravenous infusion over 30 minutes every 2 weeks until disease progression or unacceptable toxicity.

Discussing TECENTRIQ (atezolizumab) with your healthcare team Talking to Your Doctor

Discussing TECENTRIQ (atezolizumab) with your healthcare team Talking to Your Doctor Discussing TECENTRIQ (atezolizumab) with your healthcare team Talking to Your Doctor TECENTRIQ DISCUSSION SUPPORT What is TECENTRIQ? TECENTRIQ is a prescription medicine used to treat: A type of bladder

More information

Giving appropriate patients another chance to fight OPDIVO

Giving appropriate patients another chance to fight OPDIVO For dmmr/msi-h Colorectal Cancer (CRC) All individuals depicted are models used for illustrative purposes only. Who is OPDIVO for? OPDIVO is a prescription medicine used to treat colorectal cancer (a type

More information

For the Patient: USMAVFIPI

For the Patient: USMAVFIPI For the Patient: USMAVFIPI Other Names: First-Line Treatment of Unresectable or Metastatic Melanoma Using Ipilimumab U = Undesignated (requires special request) SM = Skin and Melanoma AV = Advanced F =

More information

For the Patient: USMAVNIV

For the Patient: USMAVNIV For the Patient: USMAVNIV Other Names: Treatment of Unresectable or Metastatic Melanoma Using Nivolumab U = Undesignated (requires special approval) SM = Skin and Melanoma AV = AdVanced NIV = NIVolumab

More information

For the Patient: USMAVPEM

For the Patient: USMAVPEM For the Patient: USMAVPEM Other Names: Treatment of Unresectable or Metastatic Melanoma Using Pembrolizumab U = Undesignated (requires special request) SM = Skin and Melanoma AV = Advanced PEM = Pembrolizumab

More information

For the Patient: ULUAVPMB

For the Patient: ULUAVPMB For the Patient: ULUAVPMB Other Names: Treatment of Advanced Non-Small Cell Lung Cancer Using Pembrolizumab U = Undesignated (requires special approval) LU = LUng AV = AdVanced PMB = PeMBrolizumab ABOUT

More information

HIGHLIGHTS OF PRESCRIBING INFORMATION

HIGHLIGHTS OF PRESCRIBING INFORMATION HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use OPDIVO safely and effectively. See full prescribing information for OPDIVO. OPDIVO (nivolumab) injection,

More information

Opdivo. Opdivo (nivolumab) Description

Opdivo. Opdivo (nivolumab) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.53 Subsection: Antineoplastic Agents Original Policy Date: January 16, 2015 Subject: Opdivo Page:

More information

READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION

READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION Pr OPDIVO is used to treat: Adults with skin cancer (advanced melanoma) who have not been treated and who have specific

More information

Opdivo. Opdivo (nivolumab) Description

Opdivo. Opdivo (nivolumab) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.53 Subsection: Antineoplastic nts Original Policy Date: January 16, 2015 Subject: Opdivo Page: 1 of

More information

READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION

READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION BAVENCIO (buh-ven-see-oh) Avelumab for Injection Solution for Intravenous Infusion Read this carefully before you start

More information

READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION

READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION BAVENCIO (buh-ven-see-oh) Avelumab for Injection Solution for Intravenous Infusion, 20 mg/ml Professed Standard Antineoplastic

More information

YOUR GUIDE TO TECENTRIQ (atezolizumab) non-small cell lung cancer (NSCLC)

YOUR GUIDE TO TECENTRIQ (atezolizumab) non-small cell lung cancer (NSCLC) YOUR GUIDE TO TECENTRIQ (atezolizumab) For previouslytreated advanced non-small cell lung cancer (NSCLC) ABOUT THIS BOOKLET This booklet is for people with advanced non-small cell lung cancer (NSCLC) who

More information

Important safety information to minimise the risk of immune-related adverse reactions

Important safety information to minimise the risk of immune-related adverse reactions Your Guide to KEYTRUDA (pembrolizumab) Important safety information to minimise the risk of immune-related adverse reactions Information for Patients This medicine is subject to additional monitoring.

More information

Nivolumab. Other Names: Opdivo. About this Drug. Possible Side Effects (More Common) Warnings and Precautions

Nivolumab. Other Names: Opdivo. About this Drug. Possible Side Effects (More Common) Warnings and Precautions Nivolumab Other Names: Opdivo About this Drug Nivolumab is used to treat cancer. It is given in the vein (IV). Possible Side Effects (More Common) Bone marrow depression. This is a decrease in the number

More information

READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION

READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION KEYTRUDA has been issued marketing authorization with conditions for the following patients, pending the results of

More information

system to help fight cancer Working with your immune

system to help fight cancer Working with your immune KEYTRUDA Working with your immune system to help fight cancer www.fightcancer.co.nz CONTACT DETAILS Your Oncologist/Specialist ABOUT About KEYTRUDA How KEYTRUDA works Name How KEYTRUDA works with your

More information

system to help fight cancer Working with your immune

system to help fight cancer Working with your immune KEYTRUDA Working with your immune system to help fight cancer www.fightcancer.co.nz CONTACT DETAILS Your Oncologist/Specialist Name Phone Phone (after hours) Your Specialist Nurse Name Phone Phone (after

More information

Clinical Policy: Nivolumab (Opdivo) Reference Number: ERX.SPA.302 Effective Date:

Clinical Policy: Nivolumab (Opdivo) Reference Number: ERX.SPA.302 Effective Date: Clinical Policy: (Opdivo) Reference Number: ERX.SPA.302 Effective Date: 03.01.19 Last Review Date: 02.19 Revision Log See Important Reminder at the end of this policy for important regulatory and legal

More information

Discussing TECENTRIQ (atezolizumab) with your healthcare team

Discussing TECENTRIQ (atezolizumab) with your healthcare team Discussing TECENTRIQ (atezolizumab) with your healthcare team What is TECENTRIQ? TECENTRIQ is a prescription medicine used to treat: a type of lung cancer called non-small cell lung cancer (NSCLC). TECENTRIQ

More information

Policy. Medical Policy Manual Approved Revised: Do Not Implement Until 3/2/19. Nivolumab (Intravenous)

Policy. Medical Policy Manual Approved Revised: Do Not Implement Until 3/2/19. Nivolumab (Intravenous) Nivolumab (Intravenous) NDC CODE(S) 00003-3772-XX Opdivo 40 MG/4ML SOLN (B-M SQUIBB U.S. (PRIMARY CARE)) 00003-3774-XX Opdivo 100 MG/10ML SOLN (B-M SQUIBB U.S. (PRIMARY CARE)) 00003-3734-XX Opdivo 240

More information

Summary of the Risk Management Plan (RMP) V. 1.6, July 2017 for BAVENCIO. Avelumab 200 mg/10 ml. Concentrate for Solution for Infusion

Summary of the Risk Management Plan (RMP) V. 1.6, July 2017 for BAVENCIO. Avelumab 200 mg/10 ml. Concentrate for Solution for Infusion Summary of the Risk Management Plan (RMP) V. 1.6, July 2017 for BAVENCIO Avelumab 200 mg/10 ml Concentrate for Solution for Infusion Marketing Authorisation Number 66380 Marketing Authorisation Holder:

More information

Policy. Medical Policy Manual Approved Revised: Do Not Implement until 6/30/2019. Nivolumab

Policy. Medical Policy Manual Approved Revised: Do Not Implement until 6/30/2019. Nivolumab Medical Manual Approved Revised: Do Not Implement until 6/30/2019 Nivolumab NDC CODE(S) 00003-3772-XX Opdivo 40 MG/4ML SOLN (B-M SQUIBB U.S. (PRIMARY CARE)) 00003-3774-XX Opdivo 100 MG/10ML SOLN (B-M SQUIBB

More information

Keytruda. Keytruda (pembrolizumab) Description

Keytruda. Keytruda (pembrolizumab) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.50 Subject: Keytruda Page: 1 of 9 Last Review Date: November 30, 2018 Keytruda Description Keytruda

More information

KEYTRUDA (pembrolizumab) for injection, for intravenous use KEYTRUDA (pembrolizumab) injection, for intravenous use Initial U.S.

KEYTRUDA (pembrolizumab) for injection, for intravenous use KEYTRUDA (pembrolizumab) injection, for intravenous use Initial U.S. HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use safely and effectively. See full prescribing information for. (pembrolizumab) for injection, for

More information

DOSING GUIDE. Indications. Important Safety Information. Enable the immune system. RECOGNIZE. RESPOND.

DOSING GUIDE. Indications. Important Safety Information. Enable the immune system. RECOGNIZE. RESPOND. DOSING GUIDE For patients with unresectable Stage III NSCLC following concurrent CRT For patients with locally advanced or metastatic UC previously treated with platinum-based therapy Enable the immune

More information

MEDICATION GUIDE. KEYTRUDA (key-true-duh) (pembrolizumab) for injection

MEDICATION GUIDE. KEYTRUDA (key-true-duh) (pembrolizumab) for injection (key-true-duh) (pembrolizumab) for injection MEDICATION GUIDE (key-true-duh) (pembrolizumab) injection What is the most important information I should know about? is a medicine that may treat certain cancers

More information

Your guide to taking LENVIMA for hepatocellular carcinoma (HCC), a type of liver cancer

Your guide to taking LENVIMA for hepatocellular carcinoma (HCC), a type of liver cancer Your guide to taking LENVIMA for hepatocellular carcinoma (HCC), a type of liver cancer LENVIMA is a prescription medicine that is used by itself as the first treatment for a type of liver cancer called

More information

Have a healthy discussion. Use this guide to start a. conversation. with your. healthcare provider

Have a healthy discussion. Use this guide to start a. conversation. with your. healthcare provider Have a healthy discussion Use this guide to start a conversation with your healthcare provider MAKE THE CONVERSATION COUNT Here are some things you may want to reflect on and discuss with your healthcare

More information

Keytruda. Keytruda (pembrolizumab) Description

Keytruda. Keytruda (pembrolizumab) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.50 Subject: Keytruda Page: 1 of 9 Last Review Date: September 20, 2018 Keytruda Description Keytruda

More information

What do I need to tell my doctor BEFORE I take this drug?

What do I need to tell my doctor BEFORE I take this drug? PATIENT & CAREGIVER EDUCATION Durvalumab Brand Names: US Imfinzi Brand Names: Canada Imfinzi What is this drug used for? It is used to treat cancer in the bladder or urinary tract. It is used to treat

More information

(sunitinib malate) for Kidney Cancer

(sunitinib malate) for Kidney Cancer Sutent (sunitinib malate) for Kidney Cancer Sutent is a medication used to treat adult patients with kidney cancer that has been surgically removed and at high risk of recurrence, or advanced kidney cancer

More information

KEYTRUDA (pembrolizumab) for injection, for intravenous use KEYTRUDA (pembrolizumab) injection, for intravenous use Initial U.S.

KEYTRUDA (pembrolizumab) for injection, for intravenous use KEYTRUDA (pembrolizumab) injection, for intravenous use Initial U.S. HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use safely and effectively. See full prescribing information for. (pembrolizumab) for injection, for

More information

KEYTRUDA (pembrolizumab) for injection, for intravenous use KEYTRUDA (pembrolizumab) injection, for intravenous use Initial U.S.

KEYTRUDA (pembrolizumab) for injection, for intravenous use KEYTRUDA (pembrolizumab) injection, for intravenous use Initial U.S. HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use safely and effectively. See full prescribing information for. (pembrolizumab) for injection, for

More information

Keytruda. Keytruda (pembrolizumab) Description

Keytruda. Keytruda (pembrolizumab) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.50 Subject: Keytruda Page: 1 of 7 Last Review Date: December 8, 2017 Keytruda Description Keytruda

More information

KEYTRUDA (pembrolizumab) for injection, for intravenous use KEYTRUDA (pembrolizumab) injection, for intravenous use Initial U.S.

KEYTRUDA (pembrolizumab) for injection, for intravenous use KEYTRUDA (pembrolizumab) injection, for intravenous use Initial U.S. HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use safely and effectively. See full prescribing information for. (pembrolizumab) for injection, for

More information

For males: use effective birth control during your treatment with INLYTA. Talk to your doctor about birth control methods.

For males: use effective birth control during your treatment with INLYTA. Talk to your doctor about birth control methods. PATIENT INFORMATION INLYTA (in-ly-ta) (axitinib) tablets Read this Patient Information before you start taking INLYTA and each time you get a refill. There may be new information. This information does

More information

Eloxatin Oxaliplatin concentrated solution for injection

Eloxatin Oxaliplatin concentrated solution for injection Eloxatin Oxaliplatin concentrated solution for injection Consumer Medicine Information Please read this leaflet before you are given this medicine. What is in this leaflet This leaflet answers some common

More information

QUESTIONS TO ASK MY DOCTOR

QUESTIONS TO ASK MY DOCTOR Be a part of the treatment decision by asking questions QUESTIONS TO ASK MY DOCTOR FOR PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER CYRAMZA (ramucirumab) is used with a chemotherapy called docetaxel

More information

KEYTRUDA is also indicated in combination with pemetrexed and platinum chemotherapy for the

KEYTRUDA is also indicated in combination with pemetrexed and platinum chemotherapy for the FDA-Approved Indication for KEYTRUDA (pembrolizumab) in Combination With Carboplatin and Either Paclitaxel or Nab-paclitaxel for the Firstline Treatment of Patients With Metastatic Squamous Non Small Cell

More information

Randy J. EMPLICITI patient Ready to get started

Randy J. EMPLICITI patient Ready to get started Randy J. EMPLICITI patient Ready to get started PICTURE YOUR IMMUNE SYSTEM AT WORK AGAINST MULTIPLE MYELOMA Randy J. EMPLICITI patient My body taking on multiple myeloma What is EMPLICITI? EMPLICITI is

More information

What do I need to tell my doctor BEFORE I take this drug?

What do I need to tell my doctor BEFORE I take this drug? PATIENT & CAREGIVER EDUCATION Pembrolizumab Brand Names: US Keytruda Brand Names: Canada Keytruda What is this drug used for? It is used to treat cancer. What do I need to tell my doctor BEFORE I take

More information

YOUR CABOMETYX HANDBOOK

YOUR CABOMETYX HANDBOOK YOUR CABOMETYX HANDBOOK AN OVERVIEW FOR PATIENTS AND CAREGIVERS in the full Prescribing Information. Table of Contents What s included in this handbook... 3 A kidney cancer overview...4 About CABOMETYX...4

More information

What You Need to Know About LEMTRADA (alemtuzumab) Treatment: A Patient Guide

What You Need to Know About LEMTRADA (alemtuzumab) Treatment: A Patient Guide For Patients What You Need to Know About LEMTRADA (alemtuzumab) Treatment: A Patient Guide Patients: Your doctor or nurse will go over this patient guide with you. It is important to ask any questions

More information

MEDICATION GUIDE SUTENT

MEDICATION GUIDE SUTENT MEDICATION GUIDE SUTENT (su TENT) (sunitinib malate) capsules Read the Medication Guide that comes with SUTENT before you start taking it and each time you get a refill. There may be new information. This

More information

ALECENSA (alectinib) Fact Sheet

ALECENSA (alectinib) Fact Sheet ALECENSA (alectinib) Fact Sheet What is NSCLC? ALECENSA is a kinase inhibitor approved for the treatment of people with anaplastic lymphoma kinase (ALK)-positive, metastatic non-small cell lung cancer

More information

IMMUNOTHERAPY FOR THE TREATMENT OF LUNG CANCER

IMMUNOTHERAPY FOR THE TREATMENT OF LUNG CANCER IMMUNOTHERAPY FOR THE TREATMENT OF LUNG CANCER A guide for patients and caregivers FREE TO BREATHE SUPPORT LINE (844) 835-4325 A FREE resource for lung cancer patients & caregivers About this brochure

More information

Rick N. EMPLICITI patient Ready to get started

Rick N. EMPLICITI patient Ready to get started Rick N. EMPLICITI patient Ready to get started PICTURE YOUR IMMUNE SYSTEM AT WORK AGAINST MULTIPLE MYELOMA Rick N. EMPLICITI patient My body taking on multiple myeloma What is EMPLICITI? EMPLICITI is a

More information

Page 1 of 5 VERZENIO abemaciclib tablet Eli Lilly and Company AddendaIndex Summary View All Sections HIGHLIGHTS OF PRESCRIBING INFORMATION FULL PRESCRIBING INFORMATION: CONTENTS* 1 INDICATIONS AND USAGE

More information

Clinical Policy: Nivolumab (Opdivo) Reference Number: CP.PHAR.121 Effective Date: Last Review Date: Line of Business: Medicaid

Clinical Policy: Nivolumab (Opdivo) Reference Number: CP.PHAR.121 Effective Date: Last Review Date: Line of Business: Medicaid Clinical Policy: (Opdivo) Reference Number: CP.PHAR.121 Effective Date: 07.15 Last Review Date: 01.18 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important

More information

Package leaflet: Information for the patient. Bavencio 20 mg/ml concentrate for solution for infusion avelumab

Package leaflet: Information for the patient. Bavencio 20 mg/ml concentrate for solution for infusion avelumab Package leaflet: Information for the patient Bavencio 20 mg/ml concentrate for solution for infusion avelumab This medicine is subject to additional monitoring. This will allow quick identification of

More information

Opdivo (nivolumab) An overview of Opdivo and why it is authorised in the EU. What is Opdivo and what is it used for?

Opdivo (nivolumab) An overview of Opdivo and why it is authorised in the EU. What is Opdivo and what is it used for? EMA/852560/2018 EMEA/H/C/003985 An overview of Opdivo and why it is authorised in the EU What is Opdivo and what is it used for? Opdivo is a cancer medicine used to treat the following: melanoma, a type

More information

Bristol-Myers Squibb Provides Regulatory Update in First-line Lung Cancer

Bristol-Myers Squibb Provides Regulatory Update in First-line Lung Cancer January 20, 2017 Bristol-Myers Squibb Provides Regulatory Update in First-line Lung Cancer (PRINCETON, NJ, January 19, 2017) - Bristol-Myers Squibb Company (NYSE: BMY) announced that it has decided not

More information

Inlyta (axitinib) for Kidney Cancer

Inlyta (axitinib) for Kidney Cancer Inlyta (axitinib) for Kidney Cancer Inlyta is a medication used to treat advanced kidney cancer in adults when one prior drug treatment for this disease has not worked Dosage: 5mg taken twice a day How

More information

About TARIS System and TAR-200 (GemRIS )

About TARIS System and TAR-200 (GemRIS ) TARIS and Bristol-Myers Squibb Announce Clinical Trial Collaboration Phase 1b Study to Combine TAR-200 (GemRIS ) with Opdivo (nivolumab) in the Treatment of Muscle Invasive Bladder Cancer LEXINGTON, Mass.

More information

MEDICATION GUIDE PegIntron (peg-in-tron) (Peginterferon alfa-2b) for injection, for subcutaneous use

MEDICATION GUIDE PegIntron (peg-in-tron) (Peginterferon alfa-2b) for injection, for subcutaneous use MEDICATION GUIDE PegIntron (peg-in-tron) (Peginterferon alfa-2b) for injection, for subcutaneous use If you are taking PegIntron with REBETOL (ribavirin) with or without an approved hepatitis C virus (HCV)

More information

People who have received 1-3 prior treatments for their multiple myeloma may receive: Revlimid (lenalidomide)

People who have received 1-3 prior treatments for their multiple myeloma may receive: Revlimid (lenalidomide) FINDTHE THE FIND STRENGTH STRENGTH WITHIN WITHIN TOHELP HELPFIGHT FIGHT TO MULTIPLEMYELOMA MYELOMA MULTIPLE Rick N. N. patient Rick patient What is? is a prescription medicine used with other medications

More information

Package leaflet: Information for the patient. KEYTRUDA 25 mg/ml concentrate for solution for infusion pembrolizumab

Package leaflet: Information for the patient. KEYTRUDA 25 mg/ml concentrate for solution for infusion pembrolizumab Package leaflet: Information for the patient KEYTRUDA 25 mg/ml concentrate for solution for infusion pembrolizumab This medicine is subject to additional monitoring. This will allow quick identification

More information

Dexamethasone is used to treat cancer. This drug can be given in the vein (IV), by mouth, or as an eye drop.

Dexamethasone is used to treat cancer. This drug can be given in the vein (IV), by mouth, or as an eye drop. Dexamethasone Other Names: Decadron About This Drug Dexamethasone is used to treat cancer. This drug can be given in the vein (IV), by mouth, or as an eye drop. Possible Side Effects (More Common) Increased

More information

Summary of the risk management plan (RMP) for Opdivo (nivolumab)

Summary of the risk management plan (RMP) for Opdivo (nivolumab) EMA/285771/2015 Summary of the risk management plan (RMP) for Opdivo (nivolumab) This is a summary of the risk management plan (RMP) for Opdivo, which details the measures to be taken in order to ensure

More information

Starting KAZANO gave me MORE POWER than metformin alone, with 2 medicines in 1 tablet

Starting KAZANO gave me MORE POWER than metformin alone, with 2 medicines in 1 tablet For many adults with type 2 diabetes Starting KAZANO gave me MORE POWER than metformin alone, with 2 medicines in 1 tablet Individual results may vary. Not actual patient. KAZANO is a prescription medicine

More information

Methotrexate. About This Drug. Possible Side Effects. Warnings and Precautions

Methotrexate. About This Drug. Possible Side Effects. Warnings and Precautions Methotrexate About This Drug Methotrexate is used to treat cancer. This drug is given in the vein (IV). Possible Side Effects Soreness of the mouth and throat. You may have red areas, white patches, or

More information

Attached from the following page is the press release made by BMS for your information.

Attached from the following page is the press release made by BMS for your information. September 17, 2015 Bristol-Myers Squibb s Opdivo (nivolumab) Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for Advanced Renal Cell Carcinoma (PRINCETON, NJ, September

More information

BLA /S-048, S-049, S-050, S-051, S-052, S-061, S-062, S-064, S-065, and S-066 SUPPLEMENT APPROVAL

BLA /S-048, S-049, S-050, S-051, S-052, S-061, S-062, S-064, S-065, and S-066 SUPPLEMENT APPROVAL DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration Silver Spring MD 20993 BLA 125554/S-048, S-049, S-050, S-051, S-052, S-061, S-062, S-064, S-065, and S-066 SUPPLEMENT APPROVAL Bristol-Myers

More information

Keytruda. Keytruda (pembrolizumab) Description

Keytruda. Keytruda (pembrolizumab) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.50 Subject: Keytruda Page: 1 of 6 Last Review Date: September 15, 2017 Keytruda Description Keytruda

More information

Sunitinib. Other Names: Sutent. About This Drug. Possible Side Effects. Warnings and Precautions

Sunitinib. Other Names: Sutent. About This Drug. Possible Side Effects. Warnings and Precautions Sunitinib Other Names: Sutent About This Drug Sunitnib is used to treat cancer. It is given orally (by mouth). Possible Side Effects Headache Tiredness and weakness Soreness of the mouth and throat. You

More information

QUESTIONS TO ASK MY DOCTOR

QUESTIONS TO ASK MY DOCTOR Be a part of the treatment decision by asking questions QUESTIONS TO ASK MY DOCTOR FOR PATIENTS WITH ADVANCED STOMACH OR GASTROESOPHAGEAL JUNCTION (GEJ) CANCER CYRAMZA (ramucirumab) is used alone or in

More information

I. ALL CLAIMS: HEALTH CARE PROFESSIONALS

I. ALL CLAIMS: HEALTH CARE PROFESSIONALS HCP Prescribing Information Date/Version January 2015 Version 2 Page: 1 of 5 I. ALL CLAIMS: HEALTH CARE PROFESSIONALS Indications and Usage Saxenda (liraglutide [rdna origin] injection) is indicated as

More information

MEDICATION GUIDE. BENLYSTA (ben-list-ah) (belimumab) Injection for intravenous use

MEDICATION GUIDE. BENLYSTA (ben-list-ah) (belimumab) Injection for intravenous use MEDICATION GUIDE BENLYSTA (ben-list-ah) (belimumab) Injection for intravenous use Read this Medication Guide before you start receiving BENLYSTA and before each treatment. There may be new information.

More information

GLEEVEC PATIENT RESOURCES

GLEEVEC PATIENT RESOURCES GLEEVEC TALKING WITH YOUR DOCTOR ABOUT KIT+ GIST AND ITS TREATMENT When you have KIT-positive gastrointestinal stromal tumor (KIT+ GIST), you will likely have many questions and may, at times, feel overwhelmed

More information

FOR PATIENTS WITH SYMPTOMS OF SARCOIDOSIS. Treatment Journal. H.P. Acthar Gel is a prescription medication used to treat symptoms of sarcoidosis.

FOR PATIENTS WITH SYMPTOMS OF SARCOIDOSIS. Treatment Journal. H.P. Acthar Gel is a prescription medication used to treat symptoms of sarcoidosis. FOR PATIENTS WITH SYMPTOMS OF SARCOIDOSIS Treatment Journal H.P. Acthar Gel is a prescription medication used to treat symptoms of sarcoidosis. IMPORTANT SAFETY INFORMATION Who should NOT take Acthar?

More information

For the Patient: Rituximab injection Other names: RITUXAN

For the Patient: Rituximab injection Other names: RITUXAN For the Patient: Rituximab injection Other names: RITUXAN Rituximab (ri tux' i mab) is a drug that is used to treat some types of cancer. It is a monoclonal antibody, a type of protein designed to target

More information

Tips to Help Treat Diarrhea, Nausea, and Vomiting Side Effects

Tips to Help Treat Diarrhea, Nausea, and Vomiting Side Effects Tips to Help Treat Diarrhea, Nausea, and Vomiting Side Effects If you have been prescribed OFEV (nintedanib) capsules for the treatment of idiopathic pulmonary fibrosis (IPF) this brochure can help you

More information

You should read this leaflet carefully and keep it in a safe place to refer to it later. WHAT IS OPDIVO USED FOR

You should read this leaflet carefully and keep it in a safe place to refer to it later. WHAT IS OPDIVO USED FOR (op-dee-voh) Nivolumab (nee-vol-u-mab) Consumer Medicine Information WARNINGS AND PRECAUTIONS - COMBINATION OF AND YERVOY Both and Yervoy act on your immune system and may cause inflammation in parts of

More information

Summary of the risk management plan (RMP) for Nivolumab BMS (nivolumab)

Summary of the risk management plan (RMP) for Nivolumab BMS (nivolumab) EMA/359171/2015 Summary of the risk management plan (RMP) for Nivolumab BMS (nivolumab) This is a summary of the risk management plan (RMP) for Nivolumab BMS, which details the measures to be taken in

More information

Nivolumab. Nivolumab

Nivolumab. Nivolumab Nivolumab Nivolumab This leaflet is offered as a guide to you and your family. The possible benefits of treatment vary: for some people immunotherapy may reduce the risk of the cancer coming back, for

More information

U.S. Food and Drug Administration Accepts Supplemental Biologics License Application for Opdivo

U.S. Food and Drug Administration Accepts Supplemental Biologics License Application for Opdivo U.S. Food and Drug Administration Accepts Supplemental Biologics License Application for Opdivo (nivolumab) in Patients with Previously Untreated Advanced Melanoma Application includes CheckMate -066,

More information

PRESCRIBER SAFETY BROCHURE; IMPORTANT SAFETY INFORMATION FOR THE HEALTHCARE PROVIDER

PRESCRIBER SAFETY BROCHURE; IMPORTANT SAFETY INFORMATION FOR THE HEALTHCARE PROVIDER PRESCRIBER SAFETY BROCHURE; IMPORTANT SAFETY INFORMATION FOR THE HEALTHCARE PROVIDER BEFORE STARTING YOUR PATIENTS ON SOLIRIS Important safety information for the healthcare provider Prior to initiating

More information

SELECT IMPORTANT SAFETY INFORMATION

SELECT IMPORTANT SAFETY INFORMATION Patient Wallet Card (nivolumab) is a prescription medicine used to treat metastatic melanoma, a type of skin cancer that has spread, or melanoma that cannot be removed by surgery. It is prescribed to adults

More information

Bristol-Myers Squibb Announces Regulatory Update for Opdivo (nivolumab) in Advanced Melanoma

Bristol-Myers Squibb Announces Regulatory Update for Opdivo (nivolumab) in Advanced Melanoma December 2, 2015 Bristol-Myers Squibb Announces Regulatory Update for Opdivo (nivolumab) in Advanced Melanoma (PRINCETON, NJ, November 27, 2015) Bristol-Myers Squibb Company (NYSE:BMY) announced that the

More information

Capecitabine. Other Names: Xeloda. About This Drug. Possible Side Effects. Warnings and Precautions

Capecitabine. Other Names: Xeloda. About This Drug. Possible Side Effects. Warnings and Precautions Capecitabine Other Names: Xeloda About This Drug Capecitabine is used to treat cancer. It is given orally (by mouth). Possible Side Effects Tired and weakness Loose bowel movements (diarrhea) Nausea and

More information

What is the most important information I should know about tenofovir? What should I discuss with my healthcare provider before taking tenofovir?

What is the most important information I should know about tenofovir? What should I discuss with my healthcare provider before taking tenofovir? 1 of 6 6/10/2016 4:33 PM Generic Name: tenofovir (ten OF oh vir) Brand Name: Viread What is tenofovir? Tenofovir is an antiviral medicine that prevents human immunodeficiency virus (HIV) or hepatitis B

More information

Getting started with PROMACTA (eltrombopag)

Getting started with PROMACTA (eltrombopag) Getting started with PROMACTA (eltrombopag) Indications PROMACTA is a prescription medicine used to treat adults and children 1 year and older with low blood platelet counts due to chronic immune (idiopathic)

More information

WARNINGS AND PRECAUTIONS - COMBINATION OF OPDIVO AND YERVOY

WARNINGS AND PRECAUTIONS - COMBINATION OF OPDIVO AND YERVOY OPDIVO (op-dee-voh) Nivolumab (nee-vol-u-mab) Consumer Medicine Information WARNINGS AND PRECAUTIONS - COMBINATION OF OPDIVO AND YERVOY Both OPDIVO and Yervoy act on your immune system and may cause inflammation

More information

Open to the possibility of a multiple myeloma treatment that works in cells in your body at the DNA level

Open to the possibility of a multiple myeloma treatment that works in cells in your body at the DNA level If you have multiple myeloma and have already tried at least 2 other types of treatment Open to the possibility of a multiple myeloma treatment that works in cells in your body at the DNA level What is

More information

WHAT IS OPDIVO USED FOR

WHAT IS OPDIVO USED FOR (op-dee-voh) Nivolumab (nee-vol-u-mab) Consumer Medicine Information WARNINGS AND PRECAUTIONS - COMBINATION OF AND YERVOY IN THE TREATMENT OF ADVANCED MELANOMA Both and Yervoy act on your immune system

More information

PATIENT SAFETY BROCHURE; IMPORTANT SAFETY INFORMATION FOR PATIENTS. Before starting on Soliris Important safety information for patients

PATIENT SAFETY BROCHURE; IMPORTANT SAFETY INFORMATION FOR PATIENTS. Before starting on Soliris Important safety information for patients PATIENT SAFETY BROCHURE; IMPORTANT SAFETY INFORMATION FOR PATIENTS Before starting on Soliris Important safety information for patients Before you begin Soliris (eculizumab) treatment, your physician will

More information

IMMUNOTHERAPY FOR THE TREATMENT OF LUNG CANCER

IMMUNOTHERAPY FOR THE TREATMENT OF LUNG CANCER IMMUNOTHERAPY FOR THE TREATMENT OF LUNG CANCER A guide for patients and caregivers TM Content is consistent with the Oncology Nursing Society Standards and Guidelines. The ONS Seal of Approval does not

More information

Bristol-Myers Squibb Receives FDA Approval for Opdivo

Bristol-Myers Squibb Receives FDA Approval for Opdivo February 3, 2017 Bristol-Myers Squibb Receives FDA Approval for Opdivo (nivolumab) in Previously Treated Locally Advanced or Metastatic Urothelial Carcinoma, a Type of Bladder Cancer (PRINCETON, N.J.,

More information

What You Need to Know About ARZERRA (ofatumumab)

What You Need to Know About ARZERRA (ofatumumab) Starting your treatment for chronic lymphocytic leukemia (CLL) What You Need to Know About ARZERRA (ofatumumab) Approved Use ARZERRA is a prescription medication used: With a chemotherapy drug called chlorambucil

More information

READY. SET. DOPTELET. HELP GET READY FOR YOUR UPCOMING PROCEDURE

READY. SET. DOPTELET. HELP GET READY FOR YOUR UPCOMING PROCEDURE HELP GET READY FOR YOUR UPCOMING PROCEDURE READY. SET. DOPTELET. Full Prescribing Information for DOPTELET (avatrombopag), including Patient For adults with chronic liver disease and a low platelet count

More information

Immune-Mediated Adverse Events Management Handbook

Immune-Mediated Adverse Events Management Handbook Immune-Mediated Adverse Events Management Handbook Your guide to addressing the immune-mediated adverse events (imaes) associated with patients taking PD-L1 inhibition therapy Indications and Usage IMFINZI

More information

MEDICATION GUIDE. The risk of getting a serious skin rash is higher if you:

MEDICATION GUIDE. The risk of getting a serious skin rash is higher if you: MEDICATION GUIDE Lamotrigine (lam-oh-try-jeen) Tablets USP Rx only What is the most important information I should know about lamotrigine tablets? 1. Lamotrigine tablets may cause a serious skin rash that

More information

Before starting on Soliris.

Before starting on Soliris. Before starting on Soliris. Important safety information for patients Before you begin Soliris (eculizumab) treatment, your physician will give you a: Medication Guide Soliris Patient Safety Information

More information

Preparing for Your Immune Checkpoint Inhibitor (CPI) Treatment

Preparing for Your Immune Checkpoint Inhibitor (CPI) Treatment Preparing for Your Immune Checkpoint Inhibitor (CPI) Treatment Overview What is the immune system? What are immune checkpoint inhibitors? What are the side effects to look out for? How are side effects

More information

What is the most important information I should know about bortezomib? What should I discuss with my healthcare provider before receiving bortezomib?

What is the most important information I should know about bortezomib? What should I discuss with my healthcare provider before receiving bortezomib? 1 of 5 6/10/2016 3:46 PM Generic Name: bortezomib (bor TEZ oh mib) Brand Name: Velcade What is bortezomib? Bortezomib interferes with the growth of some cancer cells and keeps them from spreading in your

More information